{
    "title": "Life-extending prostate cancer drug rejected for NHS",
    "url": "https://www.dailymail.co.uk/wires/pa/article-11184793/Life-extending-prostate-cancer-drug-rejected-NHS.html",
    "date": "2022-09-06",
    "keywords": [
        "cancer",
        "drug",
        "prostate",
        "nhs",
        "decision",
        "treatment",
        "olaparib",
        "icr",
        "care",
        "nice",
        "part",
        "cost",
        "use",
        "institute",
        "price",
        "research",
        "trial",
        "uk",
        "professor",
        "england",
        "guidance",
        "johann",
        "time",
        "scotland",
        "ireland",
        "access",
        "lifeextending",
        "dr",
        "matthew",
        "table",
        "work",
        "health",
        "excellence",
        "lynparza",
        "money",
        "london",
        "brca1",
        "brca2",
        "body",
        "evidence",
        "round",
        "abiraterone",
        "retreatment",
        "alamypa",
        "astrazeneca",
        "tablet",
        "type",
        "parp",
        "inhibitor",
        "prevent",
        "testing",
        "test",
        "directory",
        "biomarker",
        "medicine",
        "leader",
        "option",
        "tumours",
        "hobbs",
        "executive",
        "helin",
        "manufacturer",
        "negotiating",
        "agreement",
        "term",
        "government",
        "industry",
        "need",
        "counting",
        "penalty",
        "director",
        "man",
        "solution"
    ],
    "category": [
        "wires",
        "pa"
    ]
}